ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results
October 19 2012 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer products using
its Targeted Antibody Payload (TAP) technology and antibody
expertise, today announced that the Company will host a conference
call at 8:00 a.m. ET on Friday, October 26, 2012, to discuss
ImmunoGen's financial results for the three-month period ended
September 30, 2012 – the first quarter of the Company’s 2013 fiscal
year. Management also will provide an update on the Company and
more information about the economic terms of the trastuzumab
emtansine (T-DM1)-related license with Genentech, a member of the
Roche Group.
To access the live call by phone, dial 913-312-1472. Passcode:
4483380. The call also may be accessed through the Investor
Information section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through November 9, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer
therapeutics using the Company's expertise in tumor biology,
monoclonal antibodies, potent cancer-cell killing agents and
engineered linkers. The Company's TAP technology uses monoclonal
antibodies to deliver one of ImmunoGen's proprietary cancer-killing
agents specifically to tumor cells. There are now ten TAP compounds
in clinical development, of which three are wholly owned by the
Company. Marketing applications for trastuzumab emtansine (T-DM1),
the most advanced compound using ImmunoGen's TAP technology, have
been submitted in the US and Europe. Roche is developing this
compound globally under an agreement between ImmunoGen and
Genentech, a member of the Roche Group. More information about
ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024